Ameriprise’s Dyne Therapeutics DYN Stock Holding History

Ameriprise’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.95M	Sell	162,972 -34,719	-18%	-$599K	﹤0.01%	2762
2025 Q4	$3.87M	Sell	197,691 -224,965	-53%	-$4.26M	﹤0.01%	2612
2025 Q3	$5.35M	Buy	422,656 +137,652	+48%	+$1.57M	﹤0.01%	2401
2025 Q2	$2.71M	Buy	285,004 +78,039	+38%	+$859K	﹤0.01%	2776
2025 Q1	$2.16M	Sell	206,965 -12,670	-6%	-$181K	﹤0.01%	2851
2024 Q4	$5.17M	Buy	219,635 +6,735	+3%	+$199K	﹤0.01%	2329
2024 Q3	$7.65M	Buy	212,900 +186,872	+718%	+$7.44M	﹤0.01%	2042
2024 Q2	$919K	Buy	+26,028	New	+$756K	﹤0.01%	3188
2023 Q3	–	Sell	-13,300	Closed	-$150K	–	3903
2023 Q2	$150K	Sell	13,300 -36,211	-73%	-$427K	﹤0.01%	3770
2023 Q1	$570K	Buy	49,511 +26,291	+113%	+$341K	﹤0.01%	3381
2022 Q4	$269K	Hold	23,220	–	–	﹤0.01%	3621
2022 Q3	$295K	Buy	+23,220	New	+$266K	﹤0.01%	3588

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Ameriprise's DYN Position: Q1 2026 in Review

Ameriprise reduced its Dyne Therapeutics (DYN) stake by 18% in Q1 2026, selling an estimated $599K and leaving 162,972 shares worth $2.95M. The position accounts for ﹤0.01% of the portfolio, ranked #2762.

Ameriprise first reported a position in DYN in Q3 2022 and has held it in 12 quarters since. The position peaked at $7.65M in Q3 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

Ameriprise held 162,972 shares of Dyne Therapeutics worth $2.95M as of Q1 2026.
Ameriprise sold 34,719 Dyne Therapeutics shares in Q1 2026, an estimated $599K.
Dyne Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #2762 holding.
Ameriprise first reported a position in Dyne Therapeutics in Q3 2022 and has held it in 12 quarters since.
Ameriprise's Dyne Therapeutics position peaked at $7.65M in Q3 2024.
227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.